February 2022 Virtual Interim Work Group Recaps:
For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at https://member.ncpdp.org/work-groups.aspx?ID=wgmc.

Work Group 1 Telecommunication
DERFs/ECLs Reviewed:
- DERF 001879/ECL 000365 was recommended MC approve.
- DERF 001880/ECL 000366 was recommended MC approve as modified.
- DERF 001881 was pended.

Task Groups:
- The Telecommunication FAQ Task Group reviewed two DERFs, one FAQ from the WG1 Coordination of Benefits Task Group and one FAQ from an individual regarding interchangeable biosimilar products and Dispense as Written (DAW)/Product Selection Code (408-D8).
  - The Prior Authorization Transaction Consolidation Review Sub-Task Group presented recommendations to move the industry away from the Prior Authorization Transactions in the NCPDP Telecommunication Standard.
- The P and C/WC Monitoring, Billing and Education Task Group presented legislative and regulatory developments from the last quarter.
- The Coordination of Benefits (COB) Task Group presented and received approval for COB FAQ 94 – OPAP Qualifiers and Sales Tax along with DERF 001880/ECL 000366. They began review of COB FAQ 73 – Tax and Regulatory Fee Guidance for Telecommunication VF6 and the examples guide for VF6 adding and updating examples as needed and expect to put forth an updated examples guide this year. The task group also reviewed feedback from the SNIP Committee regarding suggested changes to the NCPDP Payer Sheet Template making a few minor changes and agreeing to the SNIP Committee’s changes. The NCPDP Payer Sheet Template is back with the SNIP Committee for final approval and publication.
- The Information Reporting Problems Task Group completed their review and update of NCPDP Guidance for SPAPs and ADAPs Medicare Part D Coordination of Benefits Requirements and Responsibilities but are waiting on some pictorial updates before requesting publication. The task group also published ongoing updates of the Missing Email Distribution List for 2022 plans.
- The Definition of a Valid Prescriber Task Group continued working on updates to the provider information in the Telecommunication Version D and Above Questions, Answers and Editorial Updates.
- The Benefit Integration Task Group completed their review of new fields needed for benefit synchronization. They began final review of the layout document, examples document and Benefit Integration Implementation Guide corresponding with the changes made for benefit synchronization.
- The Clinical and Safety Edits Task Group continued their review of the DUR codes and has requested input from various task groups.
- The Telecommunication Agility Next Generation (TANG) Task Group presented a summary of transition activities and responsibilities for the Telecommunication Standard transition to JSON.
• The **Pharmacy Product Locator Task Group** discussed transaction structure options and is reviewing the possibility of modeling the pharmacy product locator tool after the existing Central Fill Product Inquiry and Response transactions in the Specialized Standard.

• The **Pharmacy Services Billing Task Group** did not meet this quarter, but they are meeting in February and request industry participation and an additional task group lead.

• The **Point of Sale Rebate Review Task Group** did not meet this quarter.

• The **Eligibility Verification Enhancements Task Group** did not meet this quarter.

• The **Expand Dollar Fields Task Group** did not meet this quarter.

• The **Post Adjudication Task Group** did not meet this quarter.

• The **Standardized Subrogation Task Group** did not meet this quarter.

**Other Reportables:**

• **DSMO Change Requests**: There is no update on the status of the DSMO Change Request 1201 (New Version of the Batch Standard), 1202 (New Standard - Subrogation Implementation Guide for Batch Standard) and 1208 (New Version of the Telecommunication Standard). DNS is working on the NPRM.

• **MC REMS Workflow to Transaction Task Group, MC RTPB Standard Task Group** and the **SNIP Committee**: Recaps were provided in the WG1 download materials.

**New Business:**

• The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

• Margaret Weiker of NCPDP conducted an informal poll of the attendees for feedback on the use of the NCPDP Prior Authorization Transfer Standard and utilization of the functionality of electronically transferring prior authorization data between payers/processors.

**Work Group 2 Product Identification**

**Old Business:**

• Tammy Powell of the National Library of Medicine (NLM) provided an update on RxNorm and DailyMed.

**Task Groups:**

• The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
  
  o Reviewed and submitted to WG2 for adjudication one new QUIC form (see final adjudication determination by the Work Group in this report):
    ▪ QUIC #202104 Eli Lilly and Company TBA
  
  o Reviewed two products via email and four during task group calls for verification of the package size or billing unit to list within the drug data compendia files.
  
  o Received a presentation in December from Dr. Andrew Lindsley of Amgen about an investigational product (Tezepelumab) and its role in severe asthma. Amgen will reach out to the task group when packaging is available.
  
  o Created a new Billing Unit Standard FAQ: How to Bill for Products Containing Items Not Identified in the Package Insert or Instructions for Use? A DERF will be submitted for the May Work Group meetings.
  
  o For October through December 2021, 2,117 new Structured Product Label (SPL) Billing Unit Index files were generated with one changed SPL Billing Unit Index file based on the files received by the FDA from the compendia. The compendia group has reconciled 20 of the 22 NDCs with discrepancies.
• The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** reviewed issues resulting from the naming convention of biosimilar products and how these issues will affect provider, patient, payer and other issues concerning prior authorization for biosimilars. The task group joined the 11/18/2021 WG11 Prior Authorization Workflow-to-Transactions (ePA) Transactions Task Group call to discuss issues surrounding substitution of interchangeable biosimilars and develop a strategy for NCPDP to address. The task group is awaiting further input from the ePA Task Group.

• The **Outsourcing Facility Task Group** met to announce the FDA agreed with the request sent to an internal committee and a new SPL Marketing Category was created, Outsourcing Facility Compound Human Drug Product (Exempt from Approval Requirements) C181659. The next step will be to ask the FDA to allow Outsourcing Facility (OSF) drugs to be listed on DailyMed so they can be pulled through the system into the databases. The task group is currently working on this letter.

Other Reportables:
- **MC REMS Workflow to Transaction Task Group, MC NDC Scarcity Task Group and MC Digital Therapeutics Task Group:** Recaps for these task groups were provided in the WG2 download materials.

New Business:
- New QUIC Form Review and Final Adjudication:
  - QUIC #202104 QUIC Eli Lilly and Company TBA
    - BU = EA per section 5.1.6 and 5.1.18 of the BUS with a package quantity of 300 because non-drug entities, such as test strips, swabs, alcohol wipes or digital therapeutics, are billed as eaches and the total quantity for multi-component products, whose components share the same billing unit, is the sum of the component sizes.
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

Task Groups:
- The **Manufacturer Rebate Standard Task Group** discussed challenges with rebills and ways to develop best practices. The task group also discussed the management of retrospective errors in published versions of the Manufacturer Rebate Standard.
- The **Medical Rebate Standard Task Group** did not meet this quarter.

New Business:
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**Work Group 9 Government Programs**

Task Groups:
- The **Prescription Drug Monitoring Programs Task Group** continued monitoring state PMP activity and updated the State PMP Tracking Document, which was approved by WG9.
- The **Medicare Part D Frequently Asked Questions Task Group** developed an FAQ discussing the transition of coverage for COVID-19 vaccines from Medicare Part B Fee for Service (FFS) to Medicare Advantage (MA). The task group provided key points to assist pharmacies and Medicare
Managed Care Plans with processing COVID-19 vaccines administered on or after January 1, 2022. The work group voted to publish the new FAQ.

- The **Coordination of Benefits Contractor (COBC)/Benefits Coordination and Recovery Center (BCRC) Task Group** continued to work with RelayHealth and Wisconsin SPAP to establish a plan for June 2022 to correct the OHI and apply the N transactions correctly by creating a unique BIN/PCN for qualified plans versus non-qualified plans, updated Section 30.2 (Supplemental Type Codes) of Chapter 14 and continued to work with representatives from the BCRC to identify and resolve issues related to OHI records.
  - The **Chapter 14 Review Sub-Task Group** completed the initial review of Chapter 14 sections assigned to the sub-task group and began reviewing the entire document in preparation for submission to CMS.
  - The **Medicare Part D Section 111 Issues and Questions Sub-Task Group** worked with the BCRC to clarify Section 111 guidance, reviewed and catalogued concerns with the 2020 Proposed Rule, established a Responsible Reporting Entity (RRE)/Medicare Part D Plan contact list and provided feedback to CMS, which resulted in Query File enhancements.

- The **Hospice Task Group** reviewed and edited the Hospice Nx Processing Guidelines for Part D Plans to include definitions, processing guidelines, use case descriptions, consistency in verbiage and formatting. The task group also reviewed recommended updates to the Nx Reject Report.
- The **Medicare Financial Information Reporting (FIR) Task Group** continued making updates to the FIR Implementation Guide, continued work on the FIR scenarios document and discussed possibilities of adding references for auditors to the implementation guide.
- The **Medicare Prescription Drug Event (PDE) Task Group** discussed the CMS memo ‘Permissible Flexibilities Related to Oral Antiviral Drugs for Treatment of COVID-19 that May Receive U.S. Food and Drug Administration Emergency Use Authorization and are Procured by the U.S. Government’ and recorded questions and responses from the task group and received and discussed responses from CMS related to the Senior Savings Model.
- The **Government Programs Encounter Reporting Standard Task Group** met to review the results of November Work Group and discussed potential approaches for communicating and announcing the new standard to the industry following the ballot cycle.
- The **Medicaid Frequently Asked Questions Task Group** did not meet this quarter.
- The **340B Task Group** did not meet this quarter.
- The **Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group** did not meet this quarter.

New Business:

- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.
- Margaret Weiker of NCPDP conducted an informal poll of the attendees for feedback on the use of the NCPDP Prior Authorization Transfer Standard and utilization of the functionality of electronically transferring prior authorization data between payers/processors.

**Work Group 10 Professional Pharmacy Services**

Task Group Recaps:

- The **WG14/WG10 Standardized Medication Profile Task Group** – At the November Work Group meeting, the task group was assigned to work on Project Development Form 000056. The task group worked with the author (Dr. Reed Gelzer) of the Project Development form to clarify the project request. Dr. Gelzer rewrote the project request and resubmitted the request for MC vote during February Work Group. The task group recommended to the Work Group the project
be approved and assigned back to the task group. A request for additional task group leads was made.

- **The Identification of Social Determinants of Health Task Group** – The task group started working on a white paper for using Social Determinants of Health information in NCPDP standards. A request for additional task group leads was made.

- **The MTM and Pharmacist Clinical Services Task Group** – For the CMR Summary FHIR® wrapper, the task group decided to put this project on hold until HL7® completes the MCC eCare Plan effort’s development of a FHIR® version of an eCare Plan Summary. The FHIR® eCare Plan Summary focused on engaging the patient in their care which mirrors the requirements for the CMR summary. For the Beneficiary Level Report (BLR), the task group continued to work on a guidance document recommending a BLR standard for exchange between the provider of the MTM services to the MAPD or PDP including identification of NCPDP and/or HL7® standards.

- **The Pharmacogenomics Task Group** – On December 16, 2021, there was an NCPDP educational Pharmacogenomics (PGx) webinar titled *PGx: Model Implementations and Resources to Support the Use of Pharmacogenomics*. Robert Freimuth, PhD (Mayo Clinic) presented to the task group on HL7® PGx efforts. Xact labs presented use cases which will be added to the use case document created in 2021.

**Other Reportables:**

- **WG18 Specialty Requirements for ePrescribing Task Group, WG14 Consultant Pharmacist Interoperability Task Group** and **WG1 Pharmacy Services Billing Task Group**: Recaps for these task groups were provided in the WG10 download materials.

- **The WG1 Pharmacy Services Billing Task Group** will start meeting again in March 2022.

**Industry Updates:**

- There was an update on USP Compound Preparations Expert Panel presented by Tammy Powell.

**New Business:**

- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**Work Group 11 ePrescribing & Related Transactions**

**DERFs Reviewed:**

- DERF 001872 was pended.
- DERF 001882 was pended.
- DERF 001883 was approved.
- DERF 001884 was approved as modified.
- DERF 001885 was approved as modified.
- DERF 001886 was approved.
- DERF 001887 was approved.
- DERF 001888 was approved.

**Task Groups:**

- The **Dispensed Medication Reporting Task Group** brought forth DERF 001886.
- The **ePrescribing Regulatory Task Group** did not meet this quarter.
- The **Formulary and Benefit Task Group** brought forth DERFs 001887 and 001888. They continued working on recommendations for the Formulary and Benefit Implementation Recommendations document for the NCPDP Formulary and Benefit Standard Version 53.
• The **Implementation of Structured Sig Task Group** began looking at examples for medication administration for specific times such as 9:00 a.m. and 9:00 p.m.

• The **Pharmacy to Pharmacy Prescription Transfer Task Group** began working on new RxTransfer examples for the changes to the transactions to allow push or pull options for the transfer. The task group also provided comments to the **WG11 ePrescribing Regulatory Task Group** for the Transfer of Electronic Prescriptions for Schedules II-V Controlled Substances Between Pharmacies for Initial Filling NPRM.

• The **Prior Authorization Workflow-to-Transactions Task Group** received updates around industry activity on prior authorization, worked on topics including clarity on the use of accurate ReasonCode Values for a closed PAInitiationResponse and PAResponse transactions. The task group will be preparing comments for the Office of the National Coordinator (ONC) for Health IT and Health and Human Services (HHS) request for information around Electronic Prior Authorization Standards Implementation on their next calls.

• The **WG11/WG14 RxFill Task Group** requested to disband, and WG11 voted to approve the request.

• The **SCRIPT Implementation Recommendations Task Group** brought forth DERFs 001882, 001883, 001884 and 001885. They also received approval for several additions, modification and deletions to the **SCRIPT Implementation Recommendations** document. The two FAQs associated with Topic 305 were pended back to the task group. Their modified scope was approved.
  o The **RxChange Guidance Review Sub-Task Group** brought forth DERF 001872.

• The **XML Task Group** reviewed and provided recommendations on all submitted DERFs impacting the schema.

• The **WG14/WG11 LTPAC ePrescribing Task Group** brought forth DERF 001889. They also received approval for a new FAQ to be included in the **SCRIPT Implementation Recommendations** document.

**Other Reportables:**
- The **SCRIPT V2022011 Version Timeline** was reviewed.
- An Electronic Prescriptions for Controlled Substances (EPCS) update was provided.
- **SCRIPT Version 2017071 NSC-11** certified members were recognized.
- A NLM and RxNorm update was provided.

**New Business:**
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**Work Group 14 Long Term and Post Acute Care (LTPAC)**

**Task Groups:**
- The **Long Term and Post Acute Care Billing Issues Task Group** did not meet this quarter.
- The **Consultant Pharmacist Interoperability Task Group** completed work on updating the current C-CDA guidance document, “Consultant Pharmacist Consult Note v1.0: Guidance on the Use of the HL7® CDA Consolidated Templates for Clinical Notes R2.1 Consult Note,” to incorporate FHIR® Resources. The paper was reviewed and approved. The paper will be submitted to HL7® for the review process to co-publish the updated guidance.
- The **Long Term and Post Acute Care ePrescribing Task Group** is beginning discussions about NewRxRequest and NewRxRequestDenied to allow for LTPAC use. DERFs will be submitted in May to use sender and reviewer instead of pharmacy and provider. The task group reviewed a request
to add a new change sub-category and an update to Chapter 16 of the recommendations document. The task group also reviewed DERFs 001883 and 001889 for modifications.

- The **WG14/WG10 Standardized Medication Profile Task Group** co-published with HL7® the Standardized Medication Profile. Results of the published white paper will allow the project to proceed, which will depend upon funding and other factors, such as identification of a project resource. The task group also met with Dr. Reed Gelzer and clarified the Project Development Form 000056. The task group rewrote the project request and resubmitted the request to MC for voting.

- The **WG11/WG14 RxFill Task Group** did not meet this quarter. The task group requested to disband, and WG11 voted to approve the request.

**Other Reportables:**
- Received a LTPAC industry update.

**New Business:**
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

### Work Group 18 Specialty Pharmacy

**Task Group Recaps:**

- The **Specialty Requirements for ePrescribing Task Group** did not meet this quarter. They are encouraging all task group members to attend the **Patient Consent Task Group**. The task group will continue to work in sync with the **Patient Consent Task Group**.

- The **Specialty Pharmacy Data Exchange Task Group** continued working on the “Performance Metrics,” including structure. The task group discussed possible beta implementation of Specialty Pharmacy Data Reporting Standard — there is a pharmacy partner willing to pilot but a manufacturer partner is needed. The task group completed a survey to determine the need for a performance metrics reporting standard and reviewed the results of the survey with the group.

- The **Benefit Coverage Identification Task Group** completed and distributed a survey on benefit coverage verification. The survey currently has received 36 responses and after reviewing the responses, the task group is working on adjusting the questions to make the survey more robust. The task group reached out to X12 and they are willing to send the survey to their membership in order to get additional responses to the survey.

- The **Patient Consent Task Group** performed work supporting the two priority task group business cases within the NCPDP/HL7® Specialty Medication Enrollment FHIR® Implementation Guide, Unsolicited Consent and Consent Request/Response, from the dispenser to the prescriber/clinic. The task group completed draft implementation guide updates ([https://build.fhir.org/ig/HL7/fhir-specialty-rx](https://build.fhir.org/ig/HL7/fhir-specialty-rx)). They hosted a HL7® FHIR® Connectathon track (details and materials: [https://confluence.hl7.org/pages/viewpage.action?pageId=81004499](https://confluence.hl7.org/pages/viewpage.action?pageId=81004499)).

- The **Facilitation Access to Specialty Products Task Group** developed a recommendations paper providing information to manufacturers, prescribers, payers and pharmacies regarding hub services and limited distribution products. The task group received additional feedback from the Standardization Committee, made updates to address these revisions and sent the document back to the Standardization Committee for review.

**Other Reportables:**

- **WG10 Identification of Social Determinants of Health Task Group, WG11 Prior Authorization Workflow-to-Transaction Task Group, MC REMS Workflow to Transaction Task Group, MC Real Time Prescription Benefit Standard Task Group:** Recaps for these task groups were provided in the WG18 download materials.
New Business:
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**Work Group 45 External Standards Assessment and Implementation Guidance**

DERFs/ECLs Reviewed:
- DERF 001890 was approved.

Old Business:
- Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE and X12.

Task Groups:
- The Pharmacy and/or Combination ID Card Task Group presented an updated version of the Pharmacy and/or Combination ID Implementation Guide for publication. Updates address the Issuer ID being optional on printed cards.
- The 834/835 FAQ Task Group did not meet this quarter, but they are looking for a new task group lead.
- The Document Revisions Task Group did not meet this quarter but a new version of the CARC mapping document was published.
- The DSMO Task Group received no DSMO requests for review.

New Business:
- The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

**MC Maintenance and Control**

DERFs/ECLs: 13 new and 1 pended DERFs/ECLs were reviewed (see WG1, WG11 and WG45).
- DERF 001872 was pended.
- DERF 001879/ECL 00365 was approved.
- DERF 001880/ECL 00366 was approved as modified.
- DERF 001881 was pended.
- DERF 001882 was pended.
- DERF 01883 was approved.
- DERF 001884 was approved as modified.
- DERF 001885 was approved as modified.
- DERF 001886 was approved.
- DERF 001887 was approved.
- DERF 001888 was approved.
- DERF 001889 was approved.
- DERF 001890 was approved.
- DERF 001891 was approved as modified.

Old Business:
- Received updates from:
  - Board of Trustees
  - SNIP Committee
  - NCPDP Foundation
- Updates for the following were provided in the MC download materials:
  - HIPAA
• DSMO Change Request System (CRS) Requests No. 1201, 1202 and 1208
• Pended Project Development Form 000056 Reconciled Medication List was approved as a project with a recommendation to assign it to the existing WG14/WG10 Standardized Medication Profile Task Group.

Task Groups:
• The Education/Legislation and Regulations Task Group did not meet this quarter.
• The Emergency Preparedness Task Group updated the NCPDP Emergency Preparedness Guidance Document to add FAQs about the billing and prescribing requirements for COVID-19 oral antivirals, the billing of COVID-19 OTC home test kits and to update information about vaccine coverage under Medicare Advantage plans. The work group approved the updated document with additional modifications.
• The X12 TR3 Comment Consolidation Task Group is on hiatus and did not meet this quarter.
• The Real Time Prescription Benefit Standard (RTPB) Task Group submitted DERF 001891 to request the addition of data elements and ECL values to codify information sent in Message (504-F4). The DERF was approved by the work group. The task group discussed adding additional accumulator data elements for Medicare Part D and possible next topics from the parking lot. Following a report from the RTPB Related Law Review Sub-Task Group, the task group agreed to consider the step therapy use case of reporting the order of alternate therapies on the response.
• The Consumer and Provider RTPB Standards Monitoring Sub-Task Group identified four potential gaps between the RTPB Standard Version 12 and the HL7® FHIR® CARIN Consumer Realtime Pharmacy Benefit Check Implementation Guide. Per the HL7® Pharmacy Work Group’s direction, HL7® will be notified of these gaps via their Jira ticketing system. The sub-task group began to create a summary and description of each gap. The sub-task group’s scope was expanded to include responsibility for reviewing state legislative activity regarding consumer-facing real-time prescription benefit data exchange and comparing to the functionality in the Consumer RTPB Check transaction.
• The Related RTPB Law Review Sub-Task Group completed the review of thirteen, passed and proposed, state legislation which included provider RTPB language. Highlighted topics were discussed and recommendations developed and shared with the MC RTPB Standard Task Group.
• The Gender Transition Task Group did not meet this quarter. The task group requested to disband, and MC voted to approve the request.
• The Digital Therapeutics Task Group completed the development of a survey to solicit feedback from the digital therapeutics (DTx) industry to help determine subsequent use cases to be addressed by the task group. The survey is pending final review and the distribution list needs to be finalized. The task group is also exploring use of standards in the exchange of data between DTx manufactures and clinicians, PBMs and pharmacies.
• The NDC Scarcity Task Group began to draft a letter with NCPDP recommendations to the FDA regarding the FDA’s intent to increase the labeler code length from five digits to six digits. The intention is to send the letter in advance of the anticipated April 2022 NPRM release.
• The Definition and Use of Quantity and Day Supply Task Group continued to work on developing discrete days supply data elements for non-XML standards. The task group received input from the WG11 XML and SCRIPT Implementation Recommendations Task Groups regarding the best approach for DaysSupply in SCRIPT. The recommendation is to update the DaysSupply definition over discrete data elements or a qualifier for DaysSupply because in XML the DaysSupply representation is identified by the medication element (e.g., MedicationDispensed) in which it was sent.
• The **REMS Workflow to Transactions Task Group** continued to explore options for pharmacy transactions for REMS by evaluating the RxChange and eRx REMS transactions. It appears that RxChange transaction already have most elements needed to request and respond to REMS.

• The **NCPDP Standards Message Structure Harmonization Task Group** continued working, including revisions to address Standardization Committee feedback, on a survey to get input as to which standards may need to move or would benefit from moving to a different format. The task group decided the survey will be distributed only to NCPDP members.

New Business:

• The efforts of the Task Group Leaders were recognized. Certificates of Appreciation were mailed to the leads.

• NCPDP Most Valuable Participants were announced.

• The **MC Prior Authorization Communication, Evaluation and Recommendations (PACER) Task Group** was formed to address the next steps to streamline electronic prior authorization communications associated to prescription benefits as identified by the WG1 Prior Authorization Transaction Consolidation Review Sub-Task Group.

• Margaret Weiker of NCPDP conducted an informal poll of the attendees for feedback on the use of the NCPDP Prior Authorization Transfer Standard and utilization of the functionality of electronically transferring prior authorization data between payers/processors.